Literature DB >> 30390764

Early Detection of Ovarian Cancer.

Kevin M Elias1, Jing Guo2, Robert C Bast3.   

Abstract

Early detection of ovarian cancer could reduce mortality by 10% to 30%. Effective screening requires high sensitivity (>75%) and extremely high specificity (99.7%). Clinical trials suggest the best specificity is achieved with 2-stage strategies in which increasing serum CA125 level triggers transvaginal sonography to detect a malignant pelvic mass, although evidence for such approaches improving overall survival has been limited. Screening may be improved by combining CA125 with novel biomarkers, such as autoantibodies, circulating tumor DNA, or microRNAs. In order to detect premetastatic ovarian cancers originating in the distal fallopian tube, more sensitive approaches to diagnostic imaging are required.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoantibodies; CA125; Early detection; Ovarian cancer; Screening; TP53; ctDNA; miRNA

Mesh:

Substances:

Year:  2018        PMID: 30390764      PMCID: PMC6376972          DOI: 10.1016/j.hoc.2018.07.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  31 in total

Review 1.  Novel Approaches to Ovarian Cancer Screening.

Authors:  Denise R Nebgen; Karen H Lu; Robert C Bast
Journal:  Curr Oncol Rep       Date:  2019-07-26       Impact factor: 5.075

2.  Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.

Authors:  Michelle D Sakala; Nicole E Curci; William R Masch; Mishal Mendiratta-Lala; Erica B Stein; Ashish P Wasnik; Andrew P Sciallis; Shitanshu Uppal; Mark D Pearlman; Katherine E Maturen
Journal:  Radiol Imaging Cancer       Date:  2020-11-13

3.  miRNA-612 suppresses ovarian cancer cell tumorigenicity by downregulating NOB1.

Authors:  Zhikun Shi; Xu Zhou; Meijing Bao; Rongxia Jia; Yuqing Chu; Yang Lin
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 4.  Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.

Authors:  Juliane M Liberto; Sheng-Yin Chen; Ie-Ming Shih; Tza-Huei Wang; Tian-Li Wang; Thomas R Pisanic
Journal:  Cancers (Basel)       Date:  2022-06-11       Impact factor: 6.575

Review 5.  Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.

Authors:  A Srivastava; A Gupta; S Patidar
Journal:  Clin Transl Oncol       Date:  2021-04-11       Impact factor: 3.405

6.  Weekly cisplatin for the treatment of patients with ovarian cancer: A protocol for a systematic review of randomized controlled trial.

Authors:  Dan-Feng Zhang; Peng-Hui Dou; Dong-Xu Zhao; Jing Li; Yu-Hong Hu
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.

Authors:  Meshach Asare-Werehene; Laudine Communal; Euridice Carmona; Tien Le; Diane Provencher; Anne-Marie Mes-Masson; Benjamin K Tsang
Journal:  Sci Rep       Date:  2019-09-26       Impact factor: 4.379

Review 8.  Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview.

Authors:  Cristina Elena Staicu; Dragoș-Valentin Predescu; Călin Mircea Rusu; Beatrice Mihaela Radu; Dragos Cretoiu; Nicolae Suciu; Sanda Maria Crețoiu; Silviu-Cristian Voinea
Journal:  Cells       Date:  2020-01-09       Impact factor: 6.600

9.  Clinical significance of microRNA-125b and its contribution to ovarian carcinogenesis.

Authors:  Ya-Nan Bi; Jin-Ping Guan; Liming Wang; Ping Li; Feng-Xia Yang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

Review 10.  Multi-biomarker panel signature as the key to diagnosis of ovarian cancer.

Authors:  Thingreila Muinao; Hari Prasanna Deka Boruah; Mintu Pal
Journal:  Heliyon       Date:  2019-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.